Design Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Rating of “Hold” from Analysts

Design Therapeutics, Inc. (NASDAQ:DSGN) has received a consensus rating of “Hold” from the seven research firms that are presently covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold rating. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $5.50.

A number of research firms recently commented on DSGN. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 price objective on shares of Design Therapeutics in a research report on Wednesday, March 20th. Wedbush reaffirmed a “neutral” rating and set a $5.00 price target on shares of Design Therapeutics in a research report on Wednesday, March 20th.

Design Therapeutics Stock Down 2.1 %

Shares of NASDAQ DSGN opened at $3.69 on Friday. The firm’s 50-day moving average price is $3.02 and its 200-day moving average price is $2.58. Design Therapeutics has a 52-week low of $1.94 and a 52-week high of $8.47. The company has a market cap of $208.46 million, a PE ratio of -3.08 and a beta of 1.82.

Design Therapeutics (NASDAQ:DSGN) last posted its earnings results on Tuesday, March 19th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.11. As a group, equities research analysts anticipate that Design Therapeutics will post -1.25 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director John P. Schmid acquired 17,809 shares of the stock in a transaction dated Monday, March 25th. The shares were purchased at an average cost of $3.74 per share, with a total value of $66,605.66. Following the transaction, the director now directly owns 26,965 shares in the company, valued at $100,849.10. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director John P. Schmid acquired 17,809 shares of Design Therapeutics stock in a transaction dated Monday, March 25th. The stock was purchased at an average cost of $3.74 per share, with a total value of $66,605.66. Following the completion of the purchase, the director now directly owns 26,965 shares in the company, valued at approximately $100,849.10. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director John P. Schmid acquired 9,156 shares of the firm’s stock in a transaction dated Friday, March 22nd. The shares were purchased at an average price of $3.62 per share, for a total transaction of $33,144.72. Following the completion of the transaction, the director now directly owns 9,156 shares in the company, valued at $33,144.72. The disclosure for this purchase can be found here. Company insiders own 27.80% of the company’s stock.

Hedge Funds Weigh In On Design Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Legal & General Group Plc lifted its holdings in Design Therapeutics by 28.0% in the 2nd quarter. Legal & General Group Plc now owns 3,247 shares of the company’s stock worth $45,000 after purchasing an additional 711 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Design Therapeutics by 152.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,300 shares of the company’s stock valued at $33,000 after buying an additional 3,201 shares during the last quarter. Pale Fire Capital SE purchased a new position in shares of Design Therapeutics in the fourth quarter worth $28,000. Citigroup Inc. boosted its position in shares of Design Therapeutics by 214.5% during the second quarter. Citigroup Inc. now owns 10,716 shares of the company’s stock worth $68,000 after acquiring an additional 7,309 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in Design Therapeutics during the second quarter valued at $68,000. Institutional investors own 56.64% of the company’s stock.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.